HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Radiolabeling of cisplatin and its biodistribution in an experimental model of lung carcinogenesis.

Abstract
This study optimized the radiolabeling of cisplatin with technetium-99m (99mTc) and evaluated its biodistribution in an experimental model of lung carcinogenesis. The percentage labeling of cisplatin with 99mTc was assessed using an ascending chromatographic technique. For biodistribution studies, male rats were divided into 2 groups. The control group received normal saline intratracheally, whereas the treatment group received intratracheal administration of carcinogen 7,12-dimethylbenz(a)anthracene (DMBA) at a dose of 20 mg/kg body weight. The resulting radiopharmaceutical (99mTc-cisplatin) showed 98% labeling efficiency and was found to be stable for up to 6 hours both in both serum and saline under normal conditions. The blood clearance of the 99mTc-cisplatin followed a biphasic release pattern whereby a fast-release phase was observed at 35 seconds and a slow-release phase was observed after 30 minutes of drug administration. The biodistribution studies of control and treated animals revealed high uptake of 99mTc-cisplatin by the liver and slow excretion via the kidneys. However, a time-dependent increase in the lung-to-muscle specific uptake ratio was observed in DMBA-treated rats. The study concluded that 99mTc-cisplatin possesses selectivity toward cancerous lung tissue and can be explored further for its diagnostic potential in the detection of lung cancer and the evaluation of treatment response.
AuthorsKamal Rozy, Chatterji Piyali, Vijayta Dani Chadha
JournalJournal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer (J Environ Pathol Toxicol Oncol) Vol. 33 Issue 1 Pg. 11-7 ( 2014) ISSN: 2162-6537 [Electronic] United States
PMID24579806 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • 9,10-Dimethyl-1,2-benzanthracene
  • Technetium
  • Cisplatin
Topics
  • 9,10-Dimethyl-1,2-benzanthracene (adverse effects)
  • Animals
  • Biological Transport
  • Cisplatin (blood, pharmacokinetics)
  • Disease Models, Animal
  • Lung Neoplasms (chemically induced, metabolism, pathology)
  • Male
  • Rats
  • Rats, Sprague-Dawley
  • Technetium (blood, pharmacokinetics)
  • Tissue Distribution

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: